Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Table 2 Efficacy assessments

Parameter	Investigator assessment		IRC assessment
Parameter	Pazopanib	Sunitinib	Pazopanib	Sunitinib
Number of patients	109	100	109	100
Median PFS (1st quartile, 3rd quartile) months	13.9 (8.0, 20.2)	14.3 (5.6, 27.7)	8.3 (5.5, 19.3)	8.3 (4.1, 24.7)
HR (95% CI)	1.17 (0.792–1.727) P = 0.4381		0.99 (0.6760–1.4580) P = 0.9629
ORR, %	41	23	35	20
ORR, %	P = 0.0052		P = 0.0203

CI Confidence interval, HR Hazard ratio, IRC Independent review committee, ORR Overall response rate, PFS Progression-free survival

ISSN: 1471-2407